Outcomes with intensive treatment for acute myeloid leukemia: an analysis of two decades of data from the HARMONY Alliance

• Published in: Haematologica (Roma) 2024-11, Vol.999 (1)
• Main Authors: Sobas, Marta Anna, Turki, Amin T, Ramiro, Angela Villaverde, Sánchez, Alberto Hernández, Elicegui, Javier Martinez, González, Teresa, Melchor, Raúl Azibeiro, Abáigar, María, Tur, Laura, Dall'Olio, Daniele, Sträng, Eric, Tettero, Jesse M, Castellani, Gastone, Benner, Axel, Döhner, Konstanze, Thiede, Christian, Metzeler, Klaus H, Haferlach, Torsten, Damm, Frederik, Ayala, Rosa, Martínez-López, Joaquín, Mills, Ken I, Sierra, Jorge, Lehmann, Sören, Porta, Matteo G Della, Mayer, Jiri, Reinhardt, Dirk, Medina, Rubén Villoria, Schulze-Rath, Renate, Barbus, Martje, Hernández-Rivas, Jesús María, Huntly, Brian J P, Ossenkoppele, Gert, Döhner, Hartmut, Bullinger, Lars
• Format: Article
• Language: English
• ISSN: 0390-6078; 1592-8721; 1592-8721
• DOI: 10.3324/haematol.2024.285805

Since 2017, targeted therapies combined with conventional intensive chemotherapy have started to improve outcome of patients with acute myeloid leukemia (AML). However, even before these innovations outcomes with intensive chemotherapy have improved, which has not yet been extensively studied. Thus, we used a large pan-European multicenter dataset of the HARMONY Alliance to evaluate treatment-time dependent outcomes over two decades. In 5359 AML patients, we compared the impact of intensive induction therapy on outcome over four consecutive 5-year calendar periods from 1997 to 2016. During that time, the 5- year survival of AML patients improved significantly, also across different genetic risk groups. In particular, the 60-day mortality rate has dropped from 13.0% to 4.7% over time. The independent effect of calendar periods on outcome was confirmed in multivariate models. Improvements were documented both for patients.